Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals

International Journal of Toxicology

Volumn 30, Issue 5, 2011, Pages 583-590

  Buckley, Lorrene A ^a   Chapman, Kathryn ^b   Burns Naas, Leigh Ann ^c   Todd, Marque D ^c   Martin, Pauline L ^d   Lansita, Janice A ^e  

^a ELI LILLY AND COMPANY   (United States)

^b National Centre for the Replacement   (United Kingdom)

^c PFIZER INC   (United States)

^d CENTOCOR INC   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

biopharmaceuticals; monoclonal antibodies; nonhuman primate; safety assessment

Indexed keywords

ABATACEPT; CANAKINUMAB; CERTOLIZUMAB PEGOL; DENOSUMAB; ECULIZUMAB; INFLIXIMAB; MONOCLONAL ANTIBODY; RILONACEPT; TOCILIZUMAB; USTEKINUMAB;

CHRONIC TOXICITY; CONFERENCE PAPER; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; NONHUMAN; PRIMATE; REPRODUCTIVE TOXICITY; TOXICITY TESTING;

ANIMAL EXPERIMENTATION; ANIMAL USE ALTERNATIVES; ANIMALS; ANTIBODIES, MONOCLONAL; BIOTECHNOLOGY; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; GUIDELINES AS TOPIC; HUMANS; PRIMATES; PROGRAM DEVELOPMENT; RISK ASSESSMENT; TOXICITY TESTS;

ANIMALIA; PRIMATES;

EID: 80054800557     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581811415875     Document Type: Conference Paper

References (31)

1. Adams CP, Brantner VV. Spending on new drug development. Health Econ. 2010 ; 19 (2). 130-141
2. Cohen FJ. Macro trends in pharmaceutical innovation. Nat Rev Drug Discov. 2005 ; 4 (1). 78-84 (Pubitemid 40109592)
3. Parexels Bio/Pharmaceutical R&D Statistical Sourcebook 2008/2009. Mathieu MP, ed. Waltham: Parexel International Corporation ; 2008 :
4. Paul SM, Mytelka DS, Dunwiddie CT. How to improve R&D productivity: the pharmaceutical industrys grand challenge. Nat Rev Drug Discov. 2010 ; 9 (3). 203-214
5. Monoclonal Antibodies report part II: companies-holding mAbs in portfolio promises protection against the looming 2011-2012 patent cliff. 2007 ;:
6. Reichert JM. Monoclonal antibodies as innovative therapies. Curr Pharm Biotechnol. 2008 ; 9 (6). 423-430
7. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 2010 ; 9 (10). 767-774
8. Statistics of scientific procedures on living animals, Great Britain. 2010 ;:
9. United States Department of Agriculture Animal and Plant Health Inspection Service. Animal care annual report of activities. 2007;13. http://www.aphis.usda.gov/publications/animal-welfare/content/printable-version/ 2007-AC-Report.pdf.
10. Chapman K, Pullen N, Graham M, Ragan I. Preclinical safety testing of monoclonal antibodies: the significance of species relevance. Nat Rev Drug Discov. 2007 ; 6 (2). 120-126 (Pubitemid 46745340)
11. Chapman KL, Pullen NP, Andrews L, Ragan I. The future of non-human primate use in mAb development. Drug Discov Today. 2010 ; 15 (5-6). 236-242
12. Chapman KL, Pullen N, Coney L, et al. Preclinical development of monoclonal antibodies: considerations for the use of non-human primates. mAbs. 2009 ; 1 (5). 505-516
13. Clarke J, Hurst C, Martin P. Duration of chronic toxicity studies for biotechnology-derived pharmaceuticals: is 6 months still appropriate?. Regul Toxicol Pharmacol. 2008 ; 50 (1). 2-22 (Pubitemid 350298162)
14. Martin PL, Breslin W, Rocca M, Wright D, Cavagnaro J. Considerations in assessing the developmental and reproductive toxicity potential of biopharmaceuticals. Birth Defects Res B Dev Reprod Toxicol. 2009 ; 86 (3). 176-203
15. Bussiere JL, Martin P, Horner M. Alternative strategies for toxicity testing of species-specific biopharmaceuticals. Int J Toxicol. 2009 ; 28 (3). 230-253
16. Baldrick P. Safety evaluation of biological drugs: what are toxicology studies in primates telling us?. Reg Toxicol Pharmacol.. 2011 ; 59 (2). 227-236
17. Chapman K, Andrews L, Bajramovic J, Baldrick P, Black L, Bowman C, Buckley L, Coney L, Couch J, Dempster M, de Haan L, Pullen N, Sims J, Ragan I. The design of chronic toxicology studies of monoclonal antibodies - implications for the reduction in use of non-human primates.. :
18. Nonclinical evaluation for anticancer pharmaceuticals. ; ;..
19. Nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. ; ;..
20. Preclinical safety evaluation of biotechnology-derived pharmacueticals. ; ;..
21. Course Chairs: Buckley LA and Chapman K
22. Detection of Toxicity to Reproduction for Medicinal Products and Toxicity to Male Fertility. ; ;..
23. C , hellman GJ, Bussiere JL, Makori N, Martin PL, Ooshima Y, Weinbauer GF. Developmental and Reproductive Toxicology Studies in Nonhuman Primates. Birth Defects Res B Dev Reprod Toxicol. 2009 ; 86 (6). 446-462
24. Martin PL, Weinbauer GF. Developmental toxicity testing of biopharmaceuticals in non-human primates: previous experience and future directions. Int J Toxicol. 2010 ; 29 (6). 552-568
25. S6 Preclinical safety evaluation of biotechnology-derived pharmaceuticals. ; ;..
26. Martin PL, Zhou Z, Van den Bulck K. Pharmacology and placental transfer of a human αv integrin monoclonal antibody in rabbits. Birth Defects Res B Dev Reprod Toxicol. 2010 ; 89 (2). 116-123
27. US Package Inserts (USPIs)downloaded from the FDA website May 2011.
28. Ilaris: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 125319s000lbl.pdf. Accessed May 2011.
29. Prolia: http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/ 125320s00007lbl.pdf. Accessed May 2011.
30. Orencia: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 125118s0086lbl.pdf. Accessed May 2011.
31. Stelara: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 125261s001lbl.pdf. Accessed May 2011.